FM

Frank S. Menniti

CT Cadent Therapeutics: 10 patents #3 of 23Top 15%
Pfizer: 8 patents #651 of 5,153Top 15%
NA Novartis Ag: 6 patents #703 of 5,128Top 15%
📍 Mystic, CT: #11 of 230 inventorsTop 5%
🗺 Connecticut: #1,477 of 34,797 inventorsTop 5%
Overall (All Time): #159,451 of 4,157,543Top 4%
25
Patents All Time

Issued Patents All Time

Showing 1–25 of 25 patents

Patent #TitleCo-InventorsDate
12358929 NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger, Yuelian Xu 2025-07-15
12161624 Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B David R. Anderson, Robert A. Volkmann 2024-12-10
12162890 Heteroaromatic NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2024-12-10
12145909 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B David R. Anderson, Robert A. Volkmann 2024-11-19
11807650 NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger, Yuelian Xu 2023-11-07
11648253 Thienopyrimidinone NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2023-05-16
11541057 Thienopyrimidinone NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2023-01-03
11274107 NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger, Yuelian Xu 2022-03-15
11236104 Heteroaromatic NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2022-02-01
11116749 Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B David R. Anderson, Robert A. Volkmann 2021-09-14
10973825 Thienopyrimidinone NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2021-04-13
10781174 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B David R. Anderson, Robert A. Volkmann 2020-09-22
10626122 Heteroaromatic NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2020-04-21
10500205 Thienopyrimidinone NMDA receptor modulators and uses thereof David R. Anderson, Robert A. Volkmann, Christopher Fanger 2019-12-10
10239835 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B David R. Anderson, Robert A. Volkmann 2019-03-26
10052306 Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B David R. Anderson, Robert A. Volkmann 2018-08-21
9540324 Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B David R. Anderson, Robert A. Volkmann 2017-01-10
7078529 Imidazole derivatives Mark Sanner, Chris Helal, Christoper B. Cooper, Patricia Seymour, Michael Ahlijanian +2 more 2006-07-18
7019016 NMDA NR2B antagonists for treatment Bertrand L. Chenard, Mario Saltarelli 2006-03-28
6958351 NMDA NR2B antagonists for treatment Bertrand L. Chenard, Mario Saltarelli 2005-10-25
6821985 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury Bertrand L. Chenard, Mario Saltarelli 2004-11-23
6756385 Imidazole derivatives Mark Sanner, Chris Helal, Christoper B. Cooper, Michael Ahlijanian, Annabella Villalobos +2 more 2004-06-29
6667317 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury Bertrand L. Chenard, Mario Saltarelli 2003-12-23
6258827 Combinations for the treatment of parkinsonism containing selective NMDA antagonists Bertrand L. Chenard 2001-07-10
6136812 Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy Bertrand L. Chenard, Willard M. Welch, Jr. 2000-10-24